Evidence map›Paper›PMID 25911438›Full record

ArticleEuropean journal of clinical pharmacology2015

Analgesic use before and after oral anticoagulant initiation--a population-based study in Finland.

Jenni Ilomäki, Arja Helin-Salmivaara, Risto Huupponen, Maria Rikala, Carl M Kirkpatrick, Maarit Jaana Korhonen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Jenni IlomäkiCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, 3021, Melbourne, VIC, Australia. jenni.ilomaki@monash.edu.
Arja Helin-SalmivaaraDepartment of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland.
Risto HuupponenDepartment of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland.
Maria RikalaDepartment of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland.
Carl M KirkpatrickCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, 3021, Melbourne, VIC, Australia.
Maarit Jaana KorhonenDepartment of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland.
Monash University · AUUniversity of Turku · FIHospital District of Helsinki and Uusimaa · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDue to potential drug-drug interactions and subsequent bleeding risk, analgesic use should be reviewed when an oral anticoagulant is initiated. The aim of this study was to compare use of non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics before and after oral anticoagulant initiation.

methodsAll individuals who initiated warfarin, dabigatran, or rivaroxaban between January 2012 and September 2013 were identified from the Finnish Prescription Register. Prevalence of analgesic use during 3 months after oral anticoagulant initiation was compared to analgesic use during 4 months before initiation. Analgesics included were NSAIDs, paracetamol, paracetamol in doses ≥ 2 g/day, tramadol, and other opioids. Conditional logistic regression was used to calculate odds ratios (OR) with 95% confidence intervals (CI).

resultsIn total, 54,025 initiated warfarin, 16,894 rivaroxaban, and 1569 dabigatran. The odds of NSAID use decreased among warfarin initiators (odds ratio (OR) 0.10; 95% confidence interval (CI) 0.09-0.10); 2.6% used NSAID after initiation. In contrast, the odds of NSAID use increased among rivaroxaban (OR 3.56; 95% CI 3.37-3.75) and dabigatran initiators (OR 1.44; 95% CI 1.16-1.78). The proportions using NSAIDs after the initiation were 69 and 32%, respectively. However, NSAID use decreased among dabigatran initiators with confirmed atrial fibrillation (OR 0.46; 95% CI 0.23-0.92) and among rivaroxaban initiators with a daily dose of ≥ 15 mg (OR 0.28; 95% CI 0.19-0.40).

conclusionsThe use of NSAIDs decreases extensively among warfarin initiators which is encouraging. However, the use of NSAIDs increases among rivaroxaban and dabigatran initiators. This is a concern as the bleeding risk may increase due to potential pharmacodynamic interactions.

Indexed as

Administration, OralAgedAged, 80 and overAnalgesicsAnticoagulantsAnti-Inflammatory Agents, Non-SteroidalCross-Over StudiesDrug InteractionsFemaleFinlandHemorrhageHumansMaleMiddle AgedOdds RatioRiskAnalgesicsAnticoagulantsAnti-Inflammatory Agents, Non-Steroidal

Identifiers

PMID25911438
OpenAlexW2158085414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.